Letter: Diabesity Associates with Poor COVID-19 Outcomes among Hospitalized Patients (J Obes Metab Syndr 2021;30:149-54)

IF 4.7 Q1 ENDOCRINOLOGY & METABOLISM
T. Oh
{"title":"Letter: Diabesity Associates with Poor COVID-19 Outcomes among Hospitalized Patients (J Obes Metab Syndr 2021;30:149-54)","authors":"T. Oh","doi":"10.7570/jomes21094","DOIUrl":null,"url":null,"abstract":"J Obes Metab Syndr 2022;31:86-87 Both diabetes and obesity are related to poor health outcomes of coronavirus disease 2019 (COVID-19). Approximately half of COVID-19 mortalities involved individuals with metabolic and vascular disorders.1 Therefore, special attention should be paid to this population. A previous meta-analysis2 including 24 cohort studies showed that odds ratios (ORs) of obesity for intensive care unit admission and invasive mechanical ventilation were 1.21 and 2.05, respectively. However, since obesity and diabetes are inter-related conditions, the effects of diabetes cannot be eliminated when analyzing the impact of obesity in data including both diabetic and non-diabetic subjects. Nikniaz et al.3 reported useful findings in a paper entitled “Diabesity associates with poor COVID-19 outcomes among hospitalized patients,” which was based on their prospective hospital-based registry of COVID-19 patients in East Azerbaijan, the Iranian province with the highest prevalence of obesity (over 26.3%).4 This study analyzed data from subjects who were diagnosed with diabetes prior to COVID-19. They showed that obesity (body mass index [BMI] ≥ 30 kg/m2) is a significant risk factor for death (adjusted OR, 2.72), mechanical ventilation (1.87), and intensive care unit admission (2.41) after adjusting for age, sex, smoking status, and comorbidities. However, confounding factors still exist regarding the severity of diabetes. They obtained fasting blood glucose levels and prescription data for insulin and non-insulin therapies. Duration of diabetes, glycosylated hemoglobin level, and diabetic vascular complications should be assessed when categorizing the severity of diabetes. Furthermore, we need to consider the effects of antidiabetic medications. For example, recent national data from Korea demonstrated that the use of dipeptidyl peptidase-4 inhibitor was significantly associated with better clinical outcomes of COVID-19.5 Therefore, further detailed analysis adjusting for diabetes status is necessary to determine a direct association between obesity and COVID-19 outcomes. A higher degree of obesity was related to higher all-cause mortality among individuals with type 2 diabetes.6 During hospitalization for COVID-19, mortality was greater in severe obesity (BMI ≥ 40 kg/m2) even compared to subjects with BMI of 35– 39.9 kg/m2.7 This dose-dependent association between obesity and various outcomes of COVID-19 needs to be confirmed in subjects with diabetes and obesity. In addition, multi-ethnic group","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"31 1","pages":"86 - 87"},"PeriodicalIF":4.7000,"publicationDate":"2022-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Obesity & Metabolic Syndrome","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7570/jomes21094","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

J Obes Metab Syndr 2022;31:86-87 Both diabetes and obesity are related to poor health outcomes of coronavirus disease 2019 (COVID-19). Approximately half of COVID-19 mortalities involved individuals with metabolic and vascular disorders.1 Therefore, special attention should be paid to this population. A previous meta-analysis2 including 24 cohort studies showed that odds ratios (ORs) of obesity for intensive care unit admission and invasive mechanical ventilation were 1.21 and 2.05, respectively. However, since obesity and diabetes are inter-related conditions, the effects of diabetes cannot be eliminated when analyzing the impact of obesity in data including both diabetic and non-diabetic subjects. Nikniaz et al.3 reported useful findings in a paper entitled “Diabesity associates with poor COVID-19 outcomes among hospitalized patients,” which was based on their prospective hospital-based registry of COVID-19 patients in East Azerbaijan, the Iranian province with the highest prevalence of obesity (over 26.3%).4 This study analyzed data from subjects who were diagnosed with diabetes prior to COVID-19. They showed that obesity (body mass index [BMI] ≥ 30 kg/m2) is a significant risk factor for death (adjusted OR, 2.72), mechanical ventilation (1.87), and intensive care unit admission (2.41) after adjusting for age, sex, smoking status, and comorbidities. However, confounding factors still exist regarding the severity of diabetes. They obtained fasting blood glucose levels and prescription data for insulin and non-insulin therapies. Duration of diabetes, glycosylated hemoglobin level, and diabetic vascular complications should be assessed when categorizing the severity of diabetes. Furthermore, we need to consider the effects of antidiabetic medications. For example, recent national data from Korea demonstrated that the use of dipeptidyl peptidase-4 inhibitor was significantly associated with better clinical outcomes of COVID-19.5 Therefore, further detailed analysis adjusting for diabetes status is necessary to determine a direct association between obesity and COVID-19 outcomes. A higher degree of obesity was related to higher all-cause mortality among individuals with type 2 diabetes.6 During hospitalization for COVID-19, mortality was greater in severe obesity (BMI ≥ 40 kg/m2) even compared to subjects with BMI of 35– 39.9 kg/m2.7 This dose-dependent association between obesity and various outcomes of COVID-19 needs to be confirmed in subjects with diabetes and obesity. In addition, multi-ethnic group
信函:住院患者中糖尿病与新冠肺炎不良结局的相关性(《肥胖代谢综合杂志》2021;30:149-54)
糖尿病和肥胖都与冠状病毒病2019 (COVID-19)的不良健康结果有关。大约一半的COVID-19死亡病例涉及代谢和血管疾病患者因此,应特别注意这一人群。先前一项包括24项队列研究的荟萃分析2显示,肥胖在重症监护病房住院和有创机械通气中的比值比(ORs)分别为1.21和2.05。然而,由于肥胖和糖尿病是相互关联的疾病,在分析包括糖尿病和非糖尿病受试者在内的数据中肥胖的影响时,糖尿病的影响无法消除。Nikniaz等人3在一篇题为“住院患者中糖尿病与COVID-19预后不良相关”的论文中报告了有用的发现,该论文基于他们对东阿塞拜疆(肥胖患病率最高的伊朗省份,超过26.3%)的COVID-19患者的前瞻性医院登记4这项研究分析了在COVID-19之前被诊断患有糖尿病的受试者的数据。他们发现,在调整年龄、性别、吸烟状况和合并症后,肥胖(体重指数[BMI]≥30 kg/m2)是死亡(调整OR为2.72)、机械通气(1.87)和重症监护病房入住(2.41)的重要危险因素。然而,关于糖尿病的严重程度,混淆因素仍然存在。他们获得了空腹血糖水平以及胰岛素和非胰岛素治疗的处方数据。在对糖尿病的严重程度进行分类时,应评估糖尿病病程、糖化血红蛋白水平和糖尿病血管并发症。此外,我们需要考虑抗糖尿病药物的作用。例如,韩国最近的国家数据表明,使用二肽基肽酶-4抑制剂与COVID-19.5更好的临床结局显着相关。因此,有必要进一步详细分析调整糖尿病状况,以确定肥胖与COVID-19结局之间的直接关联。肥胖程度越高,2型糖尿病患者的全因死亡率越高在COVID-19住院期间,重度肥胖(BMI≥40 kg/m2)的死亡率高于BMI为35 - 39.9 kg/m2的受试者。2.7肥胖与COVID-19各种结局之间的剂量依赖性关联需要在糖尿病和肥胖受试者中得到证实。此外,多民族
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Obesity & Metabolic Syndrome
Journal of Obesity & Metabolic Syndrome ENDOCRINOLOGY & METABOLISM-
CiteScore
8.30
自引率
9.60%
发文量
39
审稿时长
19 weeks
期刊介绍: The journal was launched in 1992 and diverse studies on obesity have been published under the title of Journal of Korean Society for the Study of Obesity until 2004. Since 2017, volume 26, the title is now the Journal of Obesity & Metabolic Syndrome (pISSN 2508-6235, eISSN 2508-7576). The journal is published quarterly on March 30th, June 30th, September 30th and December 30th. The official title of the journal is now "Journal of Obesity & Metabolic Syndrome" and the abbreviated title is "J Obes Metab Syndr". Index words from medical subject headings (MeSH) list of Index Medicus are included in each article to facilitate article search. Some or all of the articles of this journal are included in the index of PubMed, PubMed Central, Scopus, Embase, DOAJ, Ebsco, KCI, KoreaMed, KoMCI, Science Central, Crossref Metadata Search, Google Scholar, and Emerging Sources Citation Index (ESCI).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信